Mirikizumab for chronic pouch inflammation
Treatments studied
Part of Digestive system clinical trials.
This trial tests if mirikizumab can help people with chronic inflammation of the pouch (a surgically created internal reservoir) that doesn't respond well to antibiotics or acts like Crohn's disease. It aims to see if the drug can reduce symptoms like urgency, pain, and bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have had surgery to remove your colon and create a pouch (IPAA) for ulcerative colitis.
- You have ongoing pouch inflammation that either needs constant antibiotics to control or doesn't respond to them, or you have a fistula or stricture in the pouch area.
- Your doctor is already considering starting you on mirikizumab for your pouch condition.
- You have not taken mirikizumab before and do not have certain infections or severe liver or kidney problems.
- You are not pregnant or breastfeeding, and if you could become pregnant, you use effective birth control.
- You can access the internet for study data entry.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a medication called guselkumab to antibiotics can help people with chronic or recurring pouchitis, a condition that causes inflammation in the J-pouch after ulcerative colitis surgery. Participants will take antibiotics for the first 4 weeks and guselkumab as an injection over the course of the trial.
This study tests a medicine called vedolizumab to see if it is safe and helps children and teenagers with chronic pouchitis (inflammation in the pouch after colon removal). It is for kids who have not had good results with other treatments.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This trial tests if mirikizumab can reduce deep inflammation in the intestine walls in people with active Crohn's disease. It may help heal damage that shows up on an MRI scan.
This trial is testing whether a drug called mirikizumab, given alongside surgery to repair anal fistulas, can help heal them better in people with Crohn's disease. It aims to provide a new treatment option that may improve healing and quality of life.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
Hear when a new Pouchitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.